晚期卵巢癌维持治疗试验安慰剂组的不良事件:系统综述与荟萃分析
该系统综述与荟萃分析纳入13项随机对照试验,汇总2224例接受安慰剂的患者数据,量化一线(FL)和铂敏感复发性卵巢癌(PSROC)维持治疗安慰剂组的不良事件(AE)发生率。结果显示任何级别AE在FL为93.0%、PSROC为95.2%,≥3级AE分别为14.6%和18.2%,AE相关治疗延迟、减量和停药在FL为14.4%、4.1%和2.6%,PSROC为8.4%、5.5%和2.1%。作者认为非研究药物所致的AE常见,需进一步研究更好的AE评估方法。
要点
- 一线维持治疗安慰剂组任何级别AE发生率为93.0%,≥3级AE为14.6%。
- 铂敏感复发性卵巢癌安慰剂组任何级别AE为95.2%,≥3级AE为18.2%。
- AE导致治疗延迟、减量、停药在一线分别为14.4%、4.1%、2.6%。
核心结论
- 非研究药物所致的不良事件在卵巢癌维持治疗随机对照试验的安慰剂组中常见。
- 潜在解释包括反安慰剂效应、既往治疗残留毒性或基础疾病。
- 需要进一步研究以确定更好的不良事件评估方法。
研究设计与样本
- 系统综述与荟萃分析,电子检索识别一线和铂敏感复发性卵巢癌的合格随机对照试验。
- 共纳入13项随机对照试验(一线8项,铂敏感复发性5项),2224例接受安慰剂的患者(一线1541例,铂敏感复发性683例)。
- 采用逆方差法合并安慰剂组数据,评估任何AE、总体及特定≥3级AE、AE相关治疗延迟、减量和停药的风险。
主要发现
- 任何级别AE发生率:一线93.0%,铂敏感复发性95.2%。
- ≥3级AE发生率:一线14.6%,铂敏感复发性18.2%。
- 一线设置中AE导致治疗延迟14.4%、剂量减少4.1%、停药2.6%。
- 铂敏感复发性设置中AE导致治疗延迟8.4%、剂量减少5.5%、停药2.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以确定更好的不良事件评估方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maintenance treatment is standard of care for front-line (FL) and platinum-sensitive recurrent ovarian cancer (PSROC) following response to chemotherapy. Adverse events (AEs) on maintenance therapies are common and usually attributable to investigational treatments but could also be unrelated. Randomised controlled trial (RCT) with blinded placebo design is the gold standard for determining the relative differences in efficacy and AEs between treatment arms. We performed a meta-analysis to quantify AE rates in placebo arms of RCTs to determine AEs not due to investigational agents. METHODS: We performed an electronic search to identify eligible RCTs in FL and PSROC settings. Data from placebo arms were extracted and pooled using the inverse variance method to determine the risk of any AE, overall and specific grade 3 or higher (G ≥ 3) AEs, and AE-related treatment delay, reduction and discontinuation. RESULTS: We identified 13 eligible RCTs (FL, N = 8; PSROC, N = 5) with 2224 patients who received placebo (FL, N = 1541; PSROC, N = 683). The majority experienced an AE of any grade (FL, 93.0%; PSROC, 95.2%). Substantial proportions experienced G ≥ 3 AEs (FL, 14.6%; PSROC, 18.2%). In the FL setting, AEs led to treatment delay in 14.4%, dose reduction in 4.1% and discontinuation in 2.6%. Findings were similar for PSROC: 8.4%, 5.5% and 2.1%, respectively. CONCLUSIONS: AEs not due to investigational agents are common in ovarian cancer patients in maintenance therapy RCTs. Potential explanations include the nocebo effect, residual toxicities from previous treatment or underlying disease. Further research is required to identify better approaches to assessing AEs in this population.
引用
- Simon S, Francis KE, Dalrymple JE, et al. Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2022. PMID: 35653940. doi:10.1016/j.ejca.2022.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。